Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksKier Regulatory News (KIE)

Share Price Information for Kier (KIE)

Share Price is delayed by 15 minutes
Get Live Data
217.80    6.60 (3.13%)
Bid:
217.80
Ask:
218.20
Spread: 0.40 (0.184%)
Market Cap: £947.47m
KIE Live PriceLast checked at - London Stock Exchange

Intraday Kier Share Chart

Update

11 Mar 2019 07:00

RNS Number : 4235S
Kier Group PLC
11 March 2019
 

 

 

 11 March 2019

 

KIER GROUP PLC

 

UPDATE

 

Kier Group plc (the "Company" or "the Group") today provides an update on the net debt position stated in its trading statement of 22 January 2019 and the Broadmoor Hospital redevelopment project.

The Group has revised its net debt position as at 31 December 2018 to £180.5m (from c.£130m) and, accordingly, has re-calculated its average month-end net debt for the six months ended 31 December 2018 as being c.£430m (from c.£370m).

 

In the course of preparing its FY19 interim results and finalising the 31 December 2018 net debt position, the Company identified a number of adjustments (in aggregate: £10.3m), principally relating to the Group's hedging activities, and has revised the classification of the debt (in aggregate: £40.2m) associated with certain Developments assets held for resale at 31 December 2018. The Group originally consolidated this debt balance within assets held for resale on its balance sheet; following the re-classification, the debt has been included within the Group's net debt position.

 

Of the £40.2m net debt, £9.8m relates to assets which have been sold since 1 January 2019, £14.1m relates to sales which are subject to binding sale agreements and expected to complete by 30 April 2019 and the balance of £16.3m relates to assets which are either being marketed for sale by 30 June 2019 or are under offer.

 

The Group continues to forecast a net cash position at 30 June 2019 and remains focused on reducing its average month-end net debt.

 

The Board has reviewed the operational progress and cost recovery programme of the Broadmoor Hospital redevelopment project. The first phase of the project is expected to be handed over shortly and the remaining work on the project, which accounts for less than 10% of its value, will commence shortly thereafter. The Group has recently agreed a process with the client which is designed to reach agreement with respect to the Group's entitlement to the additional costs associated with the project's delay. Following its most recent review, the Board has concluded that a non-underlying provision of £25m will be included in the Group's FY19 interim results in respect of future recoveries from the client and other third parties.

 

Whilst the Board notes the current political and economic uncertainty in the UK, and the implications for third party investment, the Group remains on course to meet its underlying FY19 expectations, with the full-year results being weighted towards the second-half of the financial year, as expected.

 

As previously announced, the Company will release its FY19 interim results on 20 March 2019.

 

- ENDS -

For further information, please contact: 

Louise Turner-Smith, Kier investor relations 

+44 (0)7976 790 012

Kier press office 

+44 (0)1767 355 903

Richard Mountain/Nick Hasell, FTI Consulting 

+44(0)20 3727 1340

 

 

 

Continued ……..

A conference call with Phil Cox (Executive Chairman) and Bev Dew (Finance Director) for analysts and investors will be held at 08.00 GMT today. Dial-in details are as follows:

 

United Kingdom

Dial-in

Tollfree/Freephone

0800 279 4827

United Kingdom, Local

Dial-in

Local

+44 (0)330 336 9401

 

Participant Passcode:

974678

 

This announcement contains inside information for the purposes of EU Regulation 596/2014. The person responsible for making this announcement on behalf of the Company is Hugh Raven, General Counsel and Company Secretary.

 

 

This announcement does not constitute an offer of securities by Kier Group plc (the "Company"). Nothing in this announcement is intended to be, or intended to be construed as, a profit forecast or a guide as to the performance, financial or otherwise, of the Company or any of its subsidiaries (together, the "Group") whether in the current or any future financial year. This announcement may include statements that are, or may be deemed to be, ''forward-looking statements''. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future and may be beyond the Company's or the Group's ability to control or predict. Forward-looking statements are not guarantees of future performance. You are advised to read the section headed ''Principal risks and uncertainties'' in the Company's Annual Report and Accounts for the year ended 30 June 2018 and the section of the Company's rights issue prospectus dated 30 November 2018 entitled "Risk factors" for a further discussion of the factors that could affect the Company's or the Group's future performance and the industry in which it operates. Other than in accordance with its legal or regulatory obligations, the Company does not accept any obligation to update or revise publicly any forward-looking statement, whether as a result of new information, future events or otherwise.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
UPDJBMATMBABMPL
Date   Source Headline
1st Nov 202210:07 amRNSTotal Voting Rights
25th Oct 20223:35 pmRNSHolding(s) in Company
24th Oct 20222:28 pmRNSDirector/PDMR Shareholding
19th Oct 20224:17 pmRNSDirector/PDMR Shareholding
12th Oct 20223:59 pmRNSHolding(s) in Company
7th Oct 202211:51 amRNSAnnual Financial Report
3rd Oct 202210:23 amRNSTotal Voting Rights
21st Sep 20223:42 pmRNSDirector/PDMR Shareholding
15th Sep 20227:00 amRNSResults for the year ended 30 June 2022
2nd Sep 202210:08 amRNSHolding(s) in Company
1st Sep 202210:21 amRNSTotal Voting Rights
22nd Aug 202210:11 amRNSDirector/PDMR Shareholding
1st Aug 202210:00 amRNSTotal Voting Rights
29th Jul 20224:05 pmRNSHolding(s) in Company
20th Jul 202212:00 pmRNSDirector/PDMR Shareholding
19th Jul 20227:00 amRNSTrading Update
6th Jul 20227:00 amRNSBoard Appointment
1st Jul 202210:16 amRNSTotal Voting Rights
1st Jul 202210:14 amRNSBlock listing Interim Review
28th Jun 20229:41 amRNSHolding(s) in Company
22nd Jun 20224:29 pmRNSHolding(s) in Company
21st Jun 202211:44 amRNSDirector/PDMR Shareholding
1st Jun 202210:36 amRNSTotal Voting Rights
24th May 20227:00 amRNSTrading Update and Capital Markets Event
20th May 20222:36 pmRNSDirector/PDMR Shareholding
3rd May 202210:30 amRNSTotal Voting Rights
29th Apr 20221:00 pmRNSDirector Declaration
19th Apr 20224:32 pmRNSDirector/PDMR Shareholding
1st Apr 202212:28 pmRNSTotal Voting Rights
21st Mar 20222:05 pmRNSDirector/PDMR Shareholding
9th Mar 20227:00 amRNSResults for the six months ended 31 December 2021
1st Mar 202212:07 pmRNSTotal Voting Rights
21st Feb 20223:08 pmRNSDirector/PDMR Shareholding
2nd Feb 20223:05 pmRNSHolding(s) in Company
1st Feb 202212:07 pmRNSTotal Voting Rights
20th Jan 202212:18 pmRNSDirector/PDMR Shareholding
20th Jan 20227:00 amRNSTrading Update
4th Jan 202212:05 pmRNSTotal Voting Rights
4th Jan 202212:00 pmRNSBlock listing Interim Review
20th Dec 20214:10 pmRNSDirector/PDMR Shareholding
1st Dec 20212:37 pmRNSTotal Voting Rights
22nd Nov 20213:14 pmRNSDirector/PDMR Shareholding
19th Nov 20212:32 pmRNSResult of AGM
15th Nov 20211:13 pmRNSHolding(s) in Company
1st Nov 20213:17 pmRNSDirector/PDMR Shareholding
1st Nov 20219:38 amRNSTotal Voting Rights
29th Oct 202112:59 pmRNSDirector/PDMR Shareholding
26th Oct 20211:00 pmRNSDirector/PDMR Shareholding
19th Oct 20213:47 pmRNSDirector/PDMR Shareholding
19th Oct 202110:00 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.